POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC
Baine MK, Febres-Aldana CA, Chang JC, Jungbluth AA, Sethi S, Antonescu CR, Travis WD, Hsieh MS, Roh MS, Homer RJ, Ladanyi M, Egger JV, Lai WV, Rudin CM, Rekhtman N. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Journal Of Thoracic Oncology 2022, 17: 1109-1121. PMID: 35760287, PMCID: PMC9427708, DOI: 10.1016/j.jtho.2022.06.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Large CellCarcinoma, NeuroendocrineGenomicsHumansLung NeoplasmsOctamer Transcription FactorsRepressor ProteinsSmall Cell Lung CarcinomaConceptsNeuroendocrine markersDiagnostic utilityLarge cell neuroendocrine carcinomaDiagnosis of SCLCSquamous cell carcinomaCell neuroendocrine carcinomaLung cancer typesMajor lung cancer typesNeuroendocrine marker expressionLung carcinoma subtypesWarrants further studyDistinct genomic alterationsClinical characteristicsCell carcinomaNeuroendocrine carcinomaLung tumorsCarcinoma subtypesLarge cohortDiagnostic mimicsTP53 alterationsMYC amplificationRecent markersTherapeutic targetingTuft cellsChallenging subset